person · Reporting owner

Peterson Kristine

Disclosed activity across 7 companies

Tapewire entity: 36325
SEC CIK: 0001508596

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMARIN CORP PLC\UKAMRN · Entity 5970	Director	June 27, 2022	June 30, 2022
ArriVent BioPharma, Inc.AVBP · Entity 4699	Director	June 18, 2026	June 23, 2026
ENANTA PHARMACEUTICALS INCENTA · Entity 5673	Director	March 11, 2026	March 13, 2026
EyePoint, Inc.EYPT · Entity 5702	Director	February 28, 2020	March 03, 2020
Immunocore Holdings plcIMCR · Entity 4544	Director	May 27, 2026	May 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMARIN CORP PLC\UK

Report date June 27, 2022 · Filed June 30, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2032-06-27	Direct	115,919	Reported balance After 2022-06-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-27 · Grant · Acquired 115,919 · Balance 115,919 F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	93,750	Reported balance After 2022-06-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-06-27 · Grant · Acquired 93,750 · Balance 93,750 F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year. F5: Not applicable. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: On June 27, 2022, the Reporting Person was granted an option to purchase 115,919 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in 2023.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer.

F4: On June 27, 2022, the Reporting Person was granted 93,750 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of June 27, 2022 or (ii) the Issuer's annual general meeting of shareholders in such year.

F5: Not applicable.

ArriVent BioPharma, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.74 · Expires 2036-06-17	Direct	13,562	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 13,562 · Balance 13,562 F1: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.

ENANTA PHARMACEUTICALS INC

Report date March 11, 2026 · Filed March 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2036-03-11	Direct	20,000	Reported balance After 2026-03-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-11 · Grant · Acquired 20,000 · Balance 20,000 F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.

EyePoint, Inc.

Report date February 28, 2020 · Filed March 03, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	19,000	Reported balance After 2020-02-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-02-28 · Grant · Acquired 19,000 · Balance 19,000 F1: Will fully vest on the one-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2030-02-28	Direct	33,500	Reported balance After 2020-02-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-02-28 · Grant · Acquired 33,500 · Balance 33,500

Filing footnotes · ownership attribution and instrument terms

F1: Will fully vest on the one-year anniversary of the grant date.

Immunocore Holdings plc

Report date May 27, 2026 · Filed May 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.52 · Expires 2036-05-26	Direct	27,492	Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 27,492 · Balance 27,492 F1: The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ImmunoGen, Inc.

Report date February 12, 2024 · Filed February 12, 2024

Section 16 reporting ended · disclosed 2024-02-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-02-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-02-12 · Disposition to issuer · Disposed 13,090 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). F2: At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the "Merger Consideration").
Deferred Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-02-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-02-12 · Disposition to issuer · Disposed 74,954 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.84 · Expires 2026-12-09	Direct	Reported balance After 2024-02-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-12 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2027-06-13	Direct	Reported balance After 2024-02-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.21 · Expires 2028-06-20	Direct	Reported balance After 2024-02-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-12 · Disposition to issuer · Disposed 18,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2029-06-20	Direct	Reported balance After 2024-02-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-02-12 · Disposition to issuer · Disposed 18,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.56 · Expires 2030-06-17	Direct	Reported balance After 2024-02-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-02-12 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2031-06-16	Direct	Reported balance After 2024-02-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2032-06-15	Direct	Reported balance After 2024-02-12 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.72 · Expires 2033-06-14	Direct	Reported balance After 2024-02-12 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-02-12 · Disposition to issuer · Disposed 19,597 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger").

F2: At the effective time of the Merger (the "Effective Time"), each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of common stock, par value $.01 per share, of the Issuer ("Common Stock") subject to such RSU immediately prior to the Effective Time, multiplied by (ii) $31.26, without interest (the "Merger Consideration").

F3: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

Paratek Pharmaceuticals, Inc.

Report date September 21, 2023 · Filed September 21, 2023

Section 16 reporting ended · disclosed 2023-09-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2023-09-21 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-09-21 · Disposition to issuer · Disposed 59,000 · Balance 20,000 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC. Row 2 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration, F4: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.61 · Expires 2031-02-18	Direct	Reported balance After 2023-09-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2030-02-19	Direct	Reported balance After 2023-09-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-09-21 · Disposition to issuer · Disposed 7,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.23 · Expires 2029-02-26	Direct	Reported balance After 2023-09-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.15 · Expires 2028-02-14	Direct	Reported balance After 2023-09-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-09-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.10 · Expires 2027-02-01	Direct	Reported balance After 2023-09-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-09-21 · Disposition to issuer · Disposed 6,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.17 · Expires 2026-03-30	Direct	Reported balance After 2023-09-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-09-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2023, by and among the Issuer, Resistance Acquisition, Inc. ("Parent"), and Resistance Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into Issuer with the Issuer being the surviving corporation (the "Merger").

F2: (Continued from Footnote 1) Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of the Issuer ("Company Common Stock") was cancelled and retired and automatically converted into the right to receive (x) $2.15, payable to the holder thereof in cash, without interest (the "Cash Consideration") but subject to reduction for any applicable withholding taxes payable in respect thereof and (y) one (1) contractual contingent value right (a "CVR Payment") that represents the right to receive $0.85 upon satisfaction of certain conditions set forth in a Contingent Value Rights Agreement, dated September 21, 2023, by and between Parent and Equiniti Trust Company, LLC.

F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award covering shares of Company Common Stock that is subject to vesting conditions based solely on continued employment or service granted under an Issuer equity plan (each, a "Company RSU") and each performance stock unit award covering shares of Company Common Stock that are subject to performance-based vesting conditions granted under an Issuer equity plan (each, a "Company PSU") (the Company RSUs and the Company PSUs, collectively "Company Equity Awards") that was then outstanding was cancelled, and the holder of such cancelled Company Equity Award is entitled, in exchange therefor, to receive (without interest and less applicable tax withholdings) (i) an amount in cash equal to the product of (A) the total number of shares of Company Common Stock subject to (or deliverable under) such Company Equity Award immediately prior to the Effective Time multiplied by (B) the Cash Consideration,

F4: (Continued from Footnote 3) and (ii) a CVR Payment for each share of Company Common Stock subject thereto (the "Equity Award Consideration"), provided, that any payment of the Equity Award Consideration in respect of an unvested Company Equity Award will remain subject to the same vesting conditions as were applicable to such Company Equity Award immediately prior to the Effective Time and shall only become payable to the holder of such cancelled Company Equity Award to the extent such vesting conditions are satisfied following the closing of the Merger.

F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was then outstanding that has an exercise price per share of Company Common Stock that is greater than $3.00 was cancelled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 18, 2021 Filed Feb 22, 2021 18:39 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantStock Option (right to buy) · Derivative	7,000	$0.00 Strike: $7.61	$0.00	Disclosure SEC source: 0000904454-21-000234 · edgar.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2031-02-18 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 18, 2021, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
February 18, 2021 Filed Feb 22, 2021 18:39 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	9,000	$0.00	$0.00	Disclosure SEC source: 0000904454-21-000234 · edgar.xml · nonDerivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 18, 2021, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document
July 13, 2020 Filed Jul 16, 2020 00:04 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantRestricted Stock Units · Derivative	27,191	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-005124 · primarydocument.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,191 Underlying: Ordinary Shares · 27,191 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On July 13, 2020, the Reporting Person was granted 27,191 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of July 13, 2020 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
July 13, 2020 Filed Jul 16, 2020 00:04 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantStock Option (Right to Buy) · Derivative	34,805	$0.00 Strike: $6.62	$0.00	Disclosure SEC source: 0001562180-20-005124 · primarydocument.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,805 Underlying: Ordinary Shares · 34,805 shares Expires 2030-07-13 F1 · derivative.exercise_date: On July 13, 2020, the Reporting Person was granted an option to purchase 34,805 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of July 13, 2020 or (ii) the Issuer's annual general meeting of shareholders in 2021. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 17, 2020 Filed Jun 18, 2020 16:07 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock Option (right to buy) · Derivative	50,000	$4.56 Strike: $4.56	$228,000.00	Disclosure SEC source: 0001179110-20-007530 · edgar.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-17 F4 · derivative.exercise_date: Exercisable as to 12,500 shares on each of 9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 17, 2020 Filed Jun 18, 2020 16:07 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	17,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-20-007530 · edgar.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,954 Underlying: Common Stock · 17,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on each of 9/1/20, 12/1/20, 3/1/21 and 6/1/21, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
February 28, 2020 Filed Mar 3, 2020 23:07 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantStock Option (Right to Buy) · Derivative	33,500	$0.00 Strike: $1.29	$0.00	Disclosure SEC source: 0001562180-20-002050 · primarydocument.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document
February 28, 2020 Filed Mar 3, 2020 23:07 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantRestricted Stock Units · Derivative	19,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-002050 · primarydocument.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document
February 26, 2020 Filed Feb 28, 2020 22:14 UTC	ENANTA PHARMACEUTICALS INC ENTA · Entity 5673	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $51.04	$0.00	Disclosure SEC source: 0001177648-20-000016 · edgar.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-02-26 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 26, 2020), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2021 annual meeting of stockholders. Read SEC document
February 19, 2020 Filed Feb 21, 2020 21:28 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantStock Option (right to buy) · Derivative	7,000	$0.00 Strike: $3.51	$0.00	Disclosure SEC source: 0000904454-20-000236 · edgar.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-02-19 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 19, 2020, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
February 19, 2020 Filed Feb 21, 2020 21:28 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	9,000	$0.00	$0.00	Disclosure SEC source: 0000904454-20-000236 · edgar.xml · nonDerivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 19, 2020, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document
June 25, 2019 Filed Jun 27, 2019 20:51 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $2.65	$0.00	Disclosure SEC source: 0001562180-19-003664 · primarydocument.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-21 Read SEC document
June 21, 2019 Filed Jun 24, 2019 20:29 UTC	EyePoint, Inc. EYPT · Entity 5702	Exercise / conversionDeferred Stock Units · Derivative	6,667	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003628 · primarydocument.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.exercise_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.expiration_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document
June 21, 2019 Filed Jun 24, 2019 20:29 UTC	EyePoint, Inc. EYPT · Entity 5702	Exercise / conversionCommon Stock	6,667	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003628 · primarydocument.xml · nonDerivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). Read SEC document
June 20, 2019 Filed Jun 24, 2019 10:25 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock Option (right to buy) · Derivative	18,000	$2.10 Strike: $2.10	$37,800.00	Disclosure SEC source: 0001179110-19-008041 · edgar.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2029-06-20 F4 · derivative.exercise_date: Exercisable as to 4,500 shares on 9/1/19, 12/1/19, 3/1/20 and 6/1/20, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 20, 2019 Filed Jun 24, 2019 10:25 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	4,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-19-008041 · edgar.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,954 Underlying: Common Stock · 4,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on 9/1/19, 12/1/19, 3/1/20 and 6/1/20, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
May 20, 2019 Filed May 22, 2019 00:09 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantRestricted Stock Units · Derivative	7,428	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-031862 · doc4.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,428 Underlying: Ordinary Shares · 7,428 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On May 20, 2019, the Reporting Person was granted 7,428 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 20, 2019 Filed May 22, 2019 00:09 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantStock Option (Right to Buy) · Derivative	9,658	$0.00 Strike: $16.83	$0.00	Disclosure SEC source: 0001209191-19-031862 · doc4.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,658 Underlying: Ordinary Shares · 9,658 shares Expires 2029-05-20 F1 · derivative.exercise_date: On May 20, 2019, the Reporting Person was granted an option to purchase 9,658 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in 2020. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 28, 2019 Filed Mar 2, 2019 01:05 UTC	ENANTA PHARMACEUTICALS INC ENTA · Entity 5673	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $102.54	$0.00	Disclosure SEC source: 0001177648-19-000022 · edgar.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2019), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2020 annual meeting of stockholders. Read SEC document
February 26, 2019 Filed Feb 28, 2019 19:35 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $7.23	$0.00	Disclosure SEC source: 0000904454-19-000287 · edgar.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-26 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 26, 2019, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
February 26, 2019 Filed Feb 28, 2019 19:35 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	7,500	$0.00	$0.00	Disclosure SEC source: 0000904454-19-000287 · edgar.xml · nonDerivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 26, 2019, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document
February 22, 2019 Filed Feb 23, 2019 02:32 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	13,500	$0.00 Strike: $5.58	$0.00	Disclosure SEC source: 0001209191-19-012806 · doc4.xml · derivative · entry 7 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,500 shares Expires 2023-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 22, 2019 Filed Feb 23, 2019 02:32 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $14.40	$0.00	Disclosure SEC source: 0001209191-19-012806 · doc4.xml · derivative · entry 6 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,000 shares Expires 2022-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 22, 2019 Filed Feb 23, 2019 02:32 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	120,000	$0.00 Strike: $3.67	$0.00	Disclosure SEC source: 0001209191-19-012806 · doc4.xml · derivative · entry 5 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 120,000 shares Expires 2020-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 22, 2019 Filed Feb 23, 2019 02:32 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	163,500	$20.02	$3,274,038.45	Disclosure SEC source: 0001209191-19-012806 · doc4.xml · nonDerivative · entry 4 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
February 22, 2019 Filed Feb 23, 2019 02:32 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	13,500	$5.58	$75,330.00	Disclosure SEC source: 0001209191-19-012806 · doc4.xml · nonDerivative · entry 3 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 22, 2019 Filed Feb 23, 2019 02:32 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	30,000	$14.40	$432,000.00	Disclosure SEC source: 0001209191-19-012806 · doc4.xml · nonDerivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 22, 2019 Filed Feb 23, 2019 02:32 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	120,000	$3.67	$440,400.00	Disclosure SEC source: 0001209191-19-012806 · doc4.xml · nonDerivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 21, 2018 Filed Jun 26, 2018 18:14 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantEmployee Stock Option (right to buy) · Derivative	40,000	$0.00 Strike: $1.95	$0.00	Disclosure SEC source: 0000899243-18-018100 · doc4.xml · derivative · entry 3 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-06-21 F3 · derivative.exercise_date: The option becomes exercisable in two equal annual installments beginning on June 21, 2019. Read SEC document
June 21, 2018 Filed Jun 26, 2018 18:14 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantDeferred Stock Units · Derivative	6,667	$0.00	$0.00	Disclosure SEC source: 0000899243-18-018100 · doc4.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document
June 21, 2018 Filed Jun 26, 2018 18:14 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantEmployee Stock Option (right to buy) · Derivative	26,667	$0.00 Strike: $1.95	$0.00	Disclosure SEC source: 0000899243-18-018100 · doc4.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,667 Underlying: Common Stock · 26,667 shares Expires 2028-06-21 Read SEC document
June 20, 2018 Filed Jun 22, 2018 14:16 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock option (right to buy) · Derivative	18,000	$11.21 Strike: $11.21	$201,780.00	Disclosure SEC source: 0001179110-18-008934 · edgar.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-20 F4 · derivative.exercise_date: Exercisable as to 4,500 shares on 9/1/18, 12/1/18, 3/1/19 and 6/1/19, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 20, 2018 Filed Jun 22, 2018 14:16 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	4,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-18-008934 · edgar.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,954 Underlying: Common Stock · 4,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on 9/1/18, 12/1/18, 3/1/19 and 6/1/19, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
May 14, 2018 Filed Oct 2, 2018 23:08 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantRestricted Stock Units · Derivative	31,153	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-053474 · doc4.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,153 Underlying: Ordinary Shares · 31,153 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On May 14, 2018, the Reporting Person was granted 31,153 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 14, 2018 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 14, 2018 Filed Oct 2, 2018 23:08 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantStock Option (right to buy) · Derivative	46,973	$0.00 Strike: $3.21	$0.00	Disclosure SEC source: 0001209191-18-053474 · doc4.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,973 Underlying: Ordinary Shares · 46,973 shares Expires 2028-05-14 F1 · derivative.exercise_date: On May 14, 2018, the Reporting Person was granted an option to purchase 46,973 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 14, 2018 or (ii) the Issuer's annual general meeting of shareholders in 2019. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 28, 2018 Filed Mar 6, 2018 00:27 UTC	ENANTA PHARMACEUTICALS INC ENTA · Entity 5673	GrantStock Option (right to buy) · Derivative	3,750	$0.00 Strike: $78.62	$0.00	Disclosure SEC source: 0001177648-18-000015 · edgar.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2028-02-28 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2018), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2019 annual meeting of stockholders. Read SEC document
February 14, 2018 Filed Feb 16, 2018 17:22 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $14.15	$0.00	Disclosure SEC source: 0000904454-18-000201 · edgar.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-02-14 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of the Issuer's common stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The stock option was granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. The stock option shall vest as to 1/12 of the shares subject to the stock option on the one-month anniversary following February 14, 2018, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. Read SEC document
February 14, 2018 Filed Feb 16, 2018 17:22 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	7,500	$0.00	$0.00	Disclosure SEC source: 0000904454-18-000201 · edgar.xml · nonDerivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of February 14, 2018, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document
December 15, 2017 Filed Dec 19, 2017 21:07 UTC	EyePoint, Inc. PSDV · Entity 5702	GrantEmployee Stock Option (right to buy) · Derivative	40,000	$0.00 Strike: $1.77	$0.00	Disclosure SEC source: 0000899243-17-029156 · doc4.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-06-27 F1 · derivative.exercise_date: The option becomes exercisable in three equal annual installments beginning on June 27, 2018. Read SEC document
September 11, 2017 Filed Sep 13, 2017 22:07 UTC	ENANTA PHARMACEUTICALS INC ENTA · Entity 5673	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $42.61	$0.00	Disclosure SEC source: 0001177648-17-000033 · edgar.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-09-11 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over three years, beginning from the date of grant (September 11, 2017). Read SEC document
June 13, 2017 Filed Jun 15, 2017 10:01 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock option (right to buy) · Derivative	10,000	$4.64 Strike: $4.64	$46,400.00	Disclosure SEC source: 0001179110-17-009095 · edgar.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-13 F4 · derivative.exercise_date: Exercisable as to 2,500 shares on 9/1/17, 12/1/17, 3/1/18 and 6/1/18, contingent upon the individual remaining a director as of each vesting date. Read SEC document
June 13, 2017 Filed Jun 15, 2017 10:01 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	3,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-17-009095 · edgar.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,954 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest quarterly on 9/1/17, 12/1/17, 3/1/18 and 6/1/18, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document
May 15, 2017 Filed May 17, 2017 21:23 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantRestricted Stock Units · Derivative	14,706	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-17-033271 · doc4.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,706 Underlying: Ordinary Shares · 14,706 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On May 15, 2017, the Reporting Person was granted 14,706 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 15, 2017 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 15, 2017 Filed May 17, 2017 21:23 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantStock Option (right to buy) · Derivative	21,146	$0.00 Strike: $3.06	$0.00	Disclosure SEC source: 0001209191-17-033271 · doc4.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,146 Underlying: Ordinary Shares · 21,146 shares Expires 2027-05-15 F1 · derivative.exercise_date: On May 15, 2017, the Reporting Person was granted an option to purchase 21,146 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 15, 2017 or (ii) the Issuer's annual general meeting of shareholders in 2018. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 02, 2017 Filed Feb 6, 2017 19:16 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $15.10	$0.00	Disclosure SEC source: 0000904454-17-000101 · edgar.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2027-02-01 F2 · derivative.exercise_price: The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant. F3 · derivative.exercise_date: The shares shall vest as to 1/12 of the shares on the one-month anniversary following February 2, 2017, and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service to the Company at each vesting date. Read SEC document
February 02, 2017 Filed Feb 6, 2017 19:16 UTC	Paratek Pharmaceuticals, Inc. PRTK · Entity 109529	GrantCommon Stock	6,000	$0.00	$0.00	Disclosure SEC source: 0000904454-17-000101 · edgar.xml · nonDerivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: The shares shall vest on the one-year anniversary of February 2, 2017, subject to the Reporting Person's continued service to the Company at the vesting date. Read SEC document
December 09, 2016 Filed Dec 13, 2016 11:08 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantStock option (right to buy) · Derivative	5,000	$1.84 Strike: $1.84	$9,200.00	Disclosure SEC source: 0001179110-16-032858 · edgar.xml · derivative · entry 2 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-12-09 F4 · derivative.exercise_date: Exercisable as to 2,500 shares commencing on March 1, 2017 and 2,500 shares commencing on June 1, 2017, contingent upon the individual remaining a director as of each vesting date. Read SEC document
December 09, 2016 Filed Dec 13, 2016 11:08 UTC	ImmunoGen, Inc. IMGN · Entity 94428	GrantDeferred Share Unit · Derivative	1,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-16-032858 · edgar.xml · derivative · entry 1 Peterson Kristine · CIK 0001508596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,954 Underlying: Common Stock · 1,500 shares Expires not disclosed F1 · derivative.exercise_price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F1 · price: The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis. F3 · derivative.exercise_date: The deferred share units vest one-half on March 1, 2017 and one-half on June 1, 2017, contingent upon the individual remaining a director as of each vesting date. F2 · derivative.exercise_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. F2 · derivative.underlying: The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.